Effect of omega3 on fetuin level
Phase 3
- Conditions
- Condition 1: chronic kidney disease. Condition 2: chronic kidney disease.Chronic kidney disease, stage 3 (moderate)Chronic kidney disease, stage 4 (severe)
- Registration Number
- IRCT20180820040839N1
- Lead Sponsor
- Shahre-kord University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
The patient above 18 years
Gleumerolar Filtration Rate between15 to 60
Exclusion Criteria
Allergen to omega3 products
Infection and inflamation disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mesurement of serum fetoin. Timepoint: Measurement of serum fetoin in the beginning of the study (before the intervention) and 90 days after medication. Method of measurement: fetoin kit in laboratory.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link omega-3 fatty acids to fetuin-A regulation in chronic kidney disease?
How do flaxseed-derived omega-3 supplements compare to fish oil in modulating fetuin levels for CKD stage 3-4 patients?
Which biomarkers correlate with fetuin-A response to omega-3 supplementation in moderate to severe chronic kidney disease?
What adverse events are associated with long-term omega-3 supplementation in CKD patients and how are they managed?
How do omega-3 fatty acids interact with other nephroprotective agents in managing CKD progression and fetuin metabolism?